(PharmaNewsWire.Com, January 28, 2017 ) ReportsWeb.com has announced the addition of the “Acute Lung Injury - Pipeline Review, H2 2016” The report outlines the evolution of enterprise content management, and identifies and assesses the best performing vendors in the market. Summary Pharmaceutical and Healthcare latest pipeline guide Acute Lung Injury - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Acute Lung Injury (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Lung Injury (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Acute Lung Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 1, 19 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 3 molecules, respectively.
Acute Lung Injury (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. For more information about this report at http://www.reportsweb.com/acute-lung-injury-pipeline-review-h2-2016 Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Lung Injury (Respiratory). - The pipeline guide reviews pipeline therapeutics for Acute Lung Injury (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Acute Lung Injury (Respiratory) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Acute Lung Injury (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Acute Lung Injury (Respiratory)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Acute Lung Injury (Respiratory). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Acute Lung Injury (Respiratory) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Request a sample copy at http://www.reportsweb.com/inquiry&RW0001530750/sample
Few Points from Table of Content: List of Tables 7 List of Figures 8 Introduction 9 Publisher Report Coverage 9 Acute Lung Injury Overview 10 Therapeutics Development 11 Pipeline Products for Acute Lung Injury - Overview 11 Pipeline Products for Acute Lung Injury - Comparative Analysis 12 Acute Lung Injury - Therapeutics under Development by Companies 13 Acute Lung Injury - Therapeutics under Investigation by Universities/Institutes 15 Acute Lung Injury - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Acute Lung Injury - Products under Development by Companies 19 Acute Lung Injury - Products under Investigation by Universities/Institutes 21 Acute Lung Injury - Companies Involved in Therapeutics Development 22 Altor BioScience Corp 22 Asklepion Pharmaceuticals LLC 23 Commence Bio Inc 24 CompleGen Inc 25 GlaxoSmithKline Plc 26 Histocell SL 27 Lung Therapeutics Inc 28 Navigen Pharmaceuticals Inc 29 Quark Pharmaceuticals Inc 30 S-Evans Biosciences Inc 31 Silence Therapeutics Plc 32 Stemedica Cell Technologies Inc 33
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
